Literature DB >> 7908118

Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweed.

C Blondin1, E Fischer, C Boisson-Vidal, M D Kazatchkine, J Jozefonvicz.   

Abstract

In the present study, we demonstrate that natural sulfated polysaccharides (fucans) isolated from brown seaweed are potent inhibitors of human complement activation. A fucan fraction of chromatographic molecular weight 22,600, termed BS8, was found to inhibit classical and alternative pathway activation in whole serum in a dose-dependent fashion. Fucan BS8 inhibited formation of the classical pathway C3 convertase by interfering with C1 activation or by inhibiting C4 cleavage and the interaction between C4b and C2. The fucan also inhibited formation/function of the alternative pathway C3 convertase by suppressing the binding of B to C3b and by interfering with the stabilizing function of Properdin. The inhibitory effect of fucans on formation of the C3 convertases was dependent on the molecular weight of the polysaccharide for compounds of chromatographic molecular weight below 16,600. Fucan had no effect on the function of the terminal complex. Since fucans were more efficient than heparin in inhibiting activation of the classical pathway in whole serum and exhibited a lesser specific anticoagulant activity on a molar basis, our results suggest that these natural sulfated polysaccharides have a potential for use as anti-complementary and anti-inflammatory agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908118     DOI: 10.1016/0161-5890(94)90121-x

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  14 in total

1.  Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate.

Authors:  Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Gerjan J Navis; Mohamed R Daha; Cees van Kooten; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

2.  Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance.

Authors:  Haining Yu; Eva M Muñoz; R Erik Edens; Robert J Linhardt
Journal:  Biochim Biophys Acta       Date:  2005-08-15

3.  Molecular cloning and characterization of a novel beta-1,3-xylanase possessing two putative carbohydrate-binding modules from a marine bacterium Vibrio sp. strain AX-4.

Authors:  Masashi Kiyohara; Keishi Sakaguchi; Kuniko Yamaguchi; Toshiyoshi Araki; Takashi Nakamura; Makoto Ito
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

4.  A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement.

Authors:  M Ling; S J Piddlesden; B P Morgan
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

Review 5.  Chemical structures and bioactivities of sulfated polysaccharides from marine algae.

Authors:  Guangling Jiao; Guangli Yu; Junzeng Zhang; H Stephen Ewart
Journal:  Mar Drugs       Date:  2011-02-08       Impact factor: 6.085

6.  Fucose-containing sulfated polysaccharides from brown seaweeds inhibit proliferation of melanoma cells and induce apoptosis by activation of caspase-3 in vitro.

Authors:  Marcel Tutor Ale; Hiroko Maruyama; Hidekazu Tamauchi; Jørn D Mikkelsen; Anne S Meyer
Journal:  Mar Drugs       Date:  2011-12-13       Impact factor: 6.085

7.  What does complement do in Alzheimer's disease? Old molecules with new insights.

Authors:  Yong Shen; Libang Yang; Rena Li
Journal:  Transl Neurodegener       Date:  2013-10-12       Impact factor: 8.014

8.  Purification of a low molecular weight fucoidan for SPECT molecular imaging of myocardial infarction.

Authors:  Pierre Saboural; Frédéric Chaubet; Francois Rouzet; Faisal Al-Shoukr; Rana Ben Azzouna; Nadia Bouchemal; Luc Picton; Liliane Louedec; Murielle Maire; Lydia Rolland; Guy Potier; Dominique Le Guludec; Didier Letourneur; Cédric Chauvierre
Journal:  Mar Drugs       Date:  2014-09-23       Impact factor: 5.118

Review 9.  Fucoidans in Nanomedicine.

Authors:  Lucas Chollet; Pierre Saboural; Cédric Chauvierre; Jean-Noël Villemin; Didier Letourneur; Frédéric Chaubet
Journal:  Mar Drugs       Date:  2016-07-29       Impact factor: 5.118

Review 10.  Fucoidan as a Potential Therapeutic for Major Blinding Diseases--A Hypothesis.

Authors:  Alexa Klettner
Journal:  Mar Drugs       Date:  2016-02-03       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.